Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze)., and Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2025 | Making CAR T-cell therapy for multiple myeloma available globally: what needs to be done?

Samir Parekh, MD, Icahn School of Medicine, Mount Sinai, New York City, NY, comments on the importance of making CAR T-cell therapy for multiple myeloma available globally. Prof. Parekh suggests that manufacturers should engage with regulatory agencies to facilitate greater acceptance and reimbursement, ultimately leading to more equitable access. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

It’s really important to get CAR-T available across the globe, particularly in lower-income countries, because it has a curative chance. And in fact, the overall burden that’s placed on patients financially may be less if we can give them CAR-T earlier. And I think in order to do this, the manufacturers of CAR-Ts, Janssen and others, should definitely approach regulatory agencies, especially with strong data coming out from early clinical trials, showing durable responses...

It’s really important to get CAR-T available across the globe, particularly in lower-income countries, because it has a curative chance. And in fact, the overall burden that’s placed on patients financially may be less if we can give them CAR-T earlier. And I think in order to do this, the manufacturers of CAR-Ts, Janssen and others, should definitely approach regulatory agencies, especially with strong data coming out from early clinical trials, showing durable responses. And this, I’m sure will lead to greater acceptance and even financial reimbursement that will allow for equitable access.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...